Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
Efficacy, safety and tolerability of an orally administered cannabis extractin the treatment of spasticity in patients with multiple sclerosis: arandomized, double-blind, placebo-controlled, crossover study
Smoked cannabis for spasticity in multiple sclerosis:a randomized, placebo-controlled trial
Sativex for the management of multiple sclerosis symptoms
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain